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In vitro-differentiated T/natural killer-cell progenitors derived
from human CD34+ cells mature in the thymus
Abstract
Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is a treatment option for patients
with hematopoietic malignancies that is hampered by treatment-related morbidity and mortality, in part
the result of opportunistic infections, a direct consequence of delayed T-cell recovery. Thymic output
can be improved by facilitation of thymic immigration, known to require precommitment of CD34(+)
cells. We demonstrate that Delta-like ligand-mediated predifferentiation of mobilized CD34(+) cells in
vitro results in a population of thymocyte-like cells arrested at a T/natural killer (NK)-cell progenitor
stage. On intrahepatic transfer to Rag2(-/-)gamma(c)(-/-) mice, these cells selectively home to the
thymus and differentiate toward surface T-cell receptor-alphabeta(+) mature T cells considerably faster
than animals transplanted with noncultured CD34(+) cells. This finding creates the opportunity to
develop an early T-cell reconstitution therapy to combine with HSCT.
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Haploidentical hematopoietic stem cell
transplantation (haplo-HSCT) is a treat-
ment option for patients with hematopoi-
etic malignancies that is hampered by
treatment-related morbidity and mortal-
ity, in part the result of opportunistic
infections, a direct consequence of de-
layed T-cell recovery. Thymic output can
be improved by facilitation of thymic immi-
gration, known to require precommitment
of CD34 cells. We demonstrate that Delta-
like ligand-mediated predifferentiation of
mobilized CD34 cells in vitro results in a
population of thymocyte-like cells ar-
rested at a T/natural killer (NK)–cell pro-
genitor stage. On intrahepatic transfer to
Rag2/c/ mice, these cells selectively
home to the thymus and differentiate to-
ward surface T-cell receptor– mature
T cells considerably faster than animals
transplanted with noncultured CD34
cells. This finding creates the opportunity
to develop an early T-cell reconstitution
therapy to combine with HSCT. (Blood.
2010;115:261-264)
Introduction
Haploidentical hematopoietic stem cell transplantation (haplo-
HSCT) has shown impressive results in the treatment of leuke-
mia.1,2 HSCT is hampered by treatment-related mortality resulting
from opportunistic infections.2-4 One obvious causative factor for
enhanced susceptibility to pathogens is the slow recovery of T cells
in the periphery.3,5 In mice, it is established that T-lineage–directed
progenitors generated in vitro have the capacity to migrate to the
thymus and complete their development into host-tolerant T cells.6,7
Because repopulation of the thymus after transplantation is consid-
ered a rate-limiting process, supplementation of in vitro pre–T-
lineage–directed cells may be one approach with potential to
improve T-cell levels after HSCT. However, not much is known
about the in vitro T-lineage commitment potential of granulocyte
colony-stimulating factor mobilized CD34 (mCD34) cells com-
monly used for haplo-HSCT. To stimulate development of T-
lineage–directed cells, we use the TSt-4 murine thymic stromal cell
line8 transduced with human Delta-like ligand (hDLL), demon-
strated to have the capacity to generate T-lineage–directed cells
from cord blood (CB) CD34 cells.9 Importantly, the T-lineage–
directed cells were arrested at the CD5CD7 stage, considered to
be the murine equivalent of double-negative 2 or 3 thymocytes, the
designated stage of T-lineage development suitable for direct
thymic reconstitution.
The goal of this study is to examine the potential of mCD34
cells to generate T-lineage–directed progenitors, determine whether
this potential is influenced by a specific Notch ligand, and
investigate whether mCD34-cell–derived progenitors have the
capacity to home to and mature in the thymus.
Methods
Cells
Purity of mobilized and CB cells, obtained after informed consent, was
more than or equal to 95% CD34 cells and less than or equal to 0.1%
contaminating CD3/CD56 cells. Natural killer (NK) cells were enriched
from peripheral blood of healthy donors using the NK isolation kit
according to the manufacturer’s instructions (Miltenyi Biotec). Informed
consent was obtained from all CD34 cell donors in accordance with the
Declaration of Helsinki. TSt-4 cell lines8-10 and K562 were grown in
standard media.
Flow cytometry
All antibodies, materials, and equipment were obtained from BD Bio-
sciences, unless stated otherwise in supplemental data (available on the
Blood website; see the Supplemental Materials link at the top of the
online article).
Coculture
mCD34 cells were seeded on monolayers of TSt-4 cells expressing Notch
ligands DLL1 or DLL4 and maintained as described.9 IL-15 (20 ng/mL;
R&D Systems) was added for differentiation toward NK-lineage. For
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transfer to mice, differentiated cells were sorted with a FACSAria. Purity of
cells was 80% to 90%.
Polymerase chain reaction analysis
Primers and positive controls used for detection of T-cell receptor (TCR)
rearrangements have been described.11
Cytotoxicity assay
A total of 2  104 fluorophor-labeled target cells (K562) were incubated
with effectors at various effector/target ratios for 4 hours. Percentages of
killed target cells were determined by flow cytometry.
Rag2/c/ mice
Mice were bred and maintained under specific pathogen–free conditions in
accordance with the guidelines of the animal facility at the Institute for
Research in Biomedicine. The Institutional Animal Care and Use Commit-
tee of the Institute for Research approved the transplantation procedure and
maintenance of the mice. Newborn injection was done as described
previously.12
Results and discussion
mCD34 cells develop into T/NK-lineage progenitors on
hDLL1/4 interaction
Sorted mCD34 cells were cultured on monolayers of TSt-4 cells
expressing either hDLL1 or hDLL4, and on TSt-4 control monolay-
ers (supplemental Figure 1). First, we analyzed the time-dependent
development of the phenotypic and genotypic markers associated
with T-lineage development in human thymus.11,13 Intracellular
CD3 (iCD3) cells became detectable after 1 week of coculture,
expanded strongly during the following weeks, and costained with
T-lineage–associated surface markers (Figure 1A; supplemental
Figure 2). After 4 weeks, the overall phenotype and percentage
distribution of the cells had stabilized, similar to the differentiation
kinetics described for CB-CD34 cells on TSt-4-hDLL1.9 Within
this time period, cell numbers had increased 200 to 600 times
(Figure 1B) with on average 50% of the cells coexpressing iCD3,
CD45RA, CD7, and CD5 (Figure 1A). Differences in overall
phenotype of the cell populations were minimal between different
mCD34 cell donors, or whether TSt-4-hDLL1 or 4 was used to
induce differentiation (Figure 1A).
To confirm T-lineage commitment, we analyzed early and late
recombination events of TCR genes, D-J and V-J/D-J,
respectively.11 After 4 weeks, T-lineage progenitors from all donors
analyzed had either partially or completely rearranged the D2-J1
genes, whereas a smaller proportion had continued with rearrange-
ment of the V-J genes (Figure 1C). There were no rearrange-
ments of D-J genes detected (not shown).
Both phenotype and genotype of the T-lineage directed cells
indicated that they were arrested at the T/NK pre-T-cell stages of
T-lineage development.11,13-15 Indeed, on transfer to TSt-4 control
monolayers, cells gradually lost the T-lineage–associated marker
CD5 (Figure 1D) and gained expression of the NK-lineage–
Figure 1. mCD34 cells develop into T/NK progeni-
tors on DLL1/4 interaction. mCD34 cells were ob-
tained from 3 donors, V1 to V3. (A) Expression of
indicated T-lineage–associated markers has stabilized
after 4 weeks of culture on TSt-4-hDLL1/4 monolayers.
For V2 and V3, the population percentage distribution of
each marker combination falls within the following ranges:
88% to 92% for CD45RAiCD3 and 45% to 55%
CD7CD5. For V1, these percentages are 63% to 68%
and 37% to 58%, respectively. (B) #Numbers/donor
represent minimum and maximum of fold increases
observed in 2 or 3 independent experiments/donor.
(C) DNA was isolated from cells cultured on TSt-4 and
TSt-4-hDLL1/4 for polymerase chain reaction analysis of
gene rearrangements at the TCR locus. At the -locus, all
donors show clear D-J rearrangement products,
whereas V-J rearrangement products are faint and
therefore must have occurred less frequently. In contrast
to positive controls, 2 products are amplified from DNA of
mCD34 cell–derived progenitors. Sequence analysis
demonstrated that the large products ( 1000 bp) are
partial rearrangements of the -locus. (D) When differen-
tiated cells were cultured for another 4 weeks on TSt-4
without DLL, the population lost surface expression of the
T-lineage–associated marker CD5. (E) Instead, cells
gained expression of the NK-lineage–associated mark-
ers NKp46 and NKG2A but did not express the killer cell
immunoglobulin-like receptor proteins CD158a-c. Again,
there are no differences between hDLL1- or hDLL4-
derived cells. Similar results were obtained with another
donor. (F) TSt-4–derived cells have killing capacity when
coincubated at indicated effector (e) target (t) ratios with
the HLA class I–negative leukemia cell line K562. Each
point represents the average of a triplicate analysis.
Similar results were obtained with another donor. Purified
peripheral blood (PB) NK cells from healthy controls
always served as positive control.
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associated markers NKp46 and NKg2A (Figure 1E). Furthermore,
the fact that the cells were able to kill the leukemia cell line K562
(Figure 1F) and did not express killer cell immunoglobulin-like
receptor ligands (Figure 1E) established that they had developed
into immature NK cells.16
T/NK progenitors fully mature on transfer to Rag2/c/ mice
To determine whether these T/NK progenitors were able to
complete their maturation in vivo, adoptive transfer experiments
were performed using Rag2/c/ mice. Figure 2A shows that
human T/NK progenitors home to the thymus of these mice and
become CD4CD8 double-positive (DP) thymocytes within
5 weeks after transfer. Furthermore, a clear population of surface
CD3 and TCR-–expressing thymocytes was observed within
7 weeks (Figure 2A). Along with the appearance of TCR-
cells, there was a concomitant decrease in total number of
huCD45 cells in these thymuses (Figure 2A). This demonstrates
that the T/NK progenitors are able to complete their TCR gene
rearrangements and implicates that a single shot of T/NK progeni-
tors provides one spatiotemporal wave of developing thymocytes.
No CD56 expression was detected in the thymus (supplemental
Figure 3), nor could huCD45 cells be found outside of the
thymus in mice given T/NK progenitors (Figure 2C), indicating
that the lineage development was restricted to T cells in
Rag2/c/ mice.
As mentioned, in T/NK progenitor–injected mice, all
huCD45 cells were CD4CD8 DP by week 5, in contrast to
animals that had received either CB- or mCD34 cells. In these
latter groups, T-lineage development was delayed by approxi-
mately 2 weeks, as percentage DP along with total number of
huCD45 cells at week 7 corresponded with week 5 data of mice
supplied with T/NK progenitors (Figure 2B; supplemental
Figure 4), confirming the advantage provided by in vitro
DLL-mediated predifferentiation.
When compared, there were not many huCD45 cells left in
bone marrow at week 7 in mCD34 cell–transplanted mice (Figure
2C). Apparently, the long-term engraftment potential of CB is
favorable over mCD34 cells in Rag2/c/ mice.
At 7 weeks, one mouse given hDLL4 T/NK progenitors had
very few huCD45 cells left in the thymus (Figure 2B-C), and none
had mature T cells in the periphery. This is not unexpected because
more than 95% of the thymocytes do not survive the positive/
negative selection process, and the underdeveloped thymuses of
Rag2/c/ mice have considerably reduced capacity. Even in
CB-CD34 cell–transplanted mice it requires continuous immigra-
tion of pro-thymocytes for 8 to 10 weeks before mature T cells can
be found outside the thymus.12
Figure 2. T/NK progenitors fully mature on transfer to Rag2/c/
mice. mCD34 were differentiated on monolayers of TSt-4 expressing
hDLL for 4 weeks, after which they were purified by cell sorting and
injected intrahepatically into newborn Rag2/c/ mice. (A) Both hDLL1-
and hDLL4-derived T/NK progenitors are found exclusively in the thymus
at both time points analyzed and have progressed toward the CD4CD8
DP stage at 4.5 weeks. A limited number of DP and few CD8 single-
positive (SP) cells already have CD3 surface expression (supplemental
Figures 3-4). The CD4 cells at this time point are immature single-
positive cells (ISP); sCD3 and CD5CD7. At 6.5 weeks, the percent-
ages of huCD45 have dropped sharply, but there is clear surface
expression of sCD3 and TCR- on T/NK progenitor-derived cells, on
both DP and CD4/CD8 SP cells (supplemental Figure 4). (B-C) Next to
T/NK progenitors, mice were given mCD34 or CB-CD34 cells. (B) Thy-
mus compartment was analyzed at indicated time points. Thymocyte
subsetting is based on coexpression of CD5 and CD7 only (double-
negative), CD4sCD3 (ISP), CD4CD8 (DP), and CD4sCD3 or
CD8sCD3 (SP). The left 2 bars of each graph represent the data from
mice displayed in panel A. Compared with mCD34 and CB-CD34 cells,
predifferentiation of mCD34 cells results in a higher percentage of cells at
the DP stage at 4.5 weeks, but few cells are left at 6.5 weeks. (C) The total
number of huCD45 cells/tissue shows that T/NK progenitors are present
temporarily and exclusively in the thymus.
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The most important finding of this study is that mCD34
cell–derived, in vitro–generated T/NK progenitors are able to
migrate to the thymus and continue their development toward
mature T cells. Conceptual similar findings were recently described
for CB-derived progenitors.17 Prospectively, cotransplantation or
sequential transplantation of CD34 cells and T/NK progenitors
will narrow the immunocompromised window of HSCT patients
considerably. Furthermore, the donor-derived thymus-matured
T cells will also contain a patient-tolerant regulatory T-cell reper-
toire that may reduce graft-versus-host disease–related
complications.
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